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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Hyperhomocysteinemia is more commonly associated with vascular
disease in Indians than in the western populations. It is caused by
genetic polymorphisms or dietary deficiencies of the B vitamins.
We attempted to identify the association of hyperhomocystein-
emia with vitamin B12 and folate in Indian patients of vascular
disease. Homocysteine, vitamin B12 and folate levels were esti-
mated in 100 controls and 100 patients of vascular disease.
Homocysteine estimation was repeated in 73 patients on different
vitamin supplements for 6 months. Homocysteine exhibited a
significant negative correlation with B12 only in cerebrovascular
disease and peripheral vascular diseasepatients, and with folate
in coronary artery disease and cerebrovascular disease patients
as well as controls. Single daily dose of folate was as effective as
a combination of folate and cobalamin in reducing plasma
homocysteine concentrations. Low levels of B12 contribute to the
higher incidence of cerebrovascular disease and peripheral
vascular disease, and low folate levels account for higher pre-
valence of hyperhomocysteinemia in coronary artery disease and
cerebrovascular disease. Moreover, irrespective of the cause of
hyperhomocysteinemia, folate is known to ameliorate it. Hence,
large-scale corrective measures like food fortification or dietary
supplementation with folate might benefit the Indian population
and reduce the incidence and morbidity of vascular disease.
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Introduction Epidemiological transition has resulted in an increase in
morbidity and mortality due to degenerative diseases such as
vascular disease. This has predominantly been seen in developing
countries, that now account for 80% of the global burden of
vascular disease.(1) In these countries, conventional markers are
often within the biological reference interval and, therefore,
cannot account for the higher incidence of vascular disease.
This has led to a search for newer markers, of which homocysteine
has emerged as a significant marker of vascular disease, especially
in patients of Asian origin.(2) Several studies have elucidated
an association of hyperhomocysteinemia with vascular disease
independent of the conventional factors.(3–6)
The association of homocysteine with vascular disease is
demonstrated to be inter-related with its role in the methionine
metabolism. In the remethylation cycle, homocysteine metabolism
is integrally related to the folate cycle (Fig. 1), where circulating
folate is converted to tetrahydrofolate (THF). This, on methyla-
tion, yields 5,10 methylene THF, which is then reduced to 5-methyl
THF by the action of the enzyme methylene tetrahydrofolate
reductase (MTHFR). The remethylation cycle is so named as
homocysteine gets remethylated to methionine by acquiring a
methyl group from 5-methyl THF from the folate cycle through
a reaction catalysed by the enzyme methionine synthase that
requires vitamin B12 as a cofactor. Hence, folate and vitamin B12
are both necessary for the remethylation of homocysteine.
The methionine, thus yielded, is further converted to S-adenosyl
methionine (SAM), the universal methyl donor of the human
metabolism. If SAM production is deficient, there results a hypo-
methylation of several proteins and DNA causing a destabilisation
of these molecules. Ultimately, this translates into synthesis of
defective proteins and collagen resulting in vascular structures
and neurons that are more susceptible to damage and apoptosis.(7)
Thus, it follows that homocysteine metabolism is dependent on
folate and vitamin B12. Deficiencies of these vitamins would result
in hyperhomocysteinemia.(8,9) Several studies have demonstrated
an association of deficiency of B12 and folate with raised plasma
homocysteine concentration.(10) This may acquire more impor-
tance in developing countries, like India, where the burden of
vascular disease is compounded by the continuing burden of
nutritional deficiencies—the double burden.(1) In such countries,
it would, therefore, be pertinent to institute measures to reduce
both nutritional deficiencies as well as risk of vascular disease.
This study was therefore conducted to assess the role of vitamin
B12 and folate deficiencies as a cause of hyperhomocysteinemia in
North Indian patients of vascular disease and, thereby, assess the
justification of food fortification for preventing vascular disease.
Materials and Methods
The project was approved by the Hospital Ethics Committee as
conforming to the Declaration of Helsinki. One hundred patients
were selected amongst those who had been admitted to Sir Ganga
Ram Hospital, New Delhi, India, in the departments of neurology,
or cardiology/cardiac surgery, or amongst those who were being
treated for peripheral vascular disease on an out-patient or in-
patient basis. Informed consent was obtained from all subjects.
They were then categorised as per the type of disease and the
diagnoses confirmed by ultrasonography, angiography, computer-
ised axial tomography (CAT) scan and Doppler studies (by
Duplex Sonography). Of these, thirty-five patients were diagnosed
as coronary artery disease (CAD), 35 as cerebrovascular disease
(CVD), and 30 as peripheral vascular disease (PVD). One hundred
healthy controls were selected who had no personal or family
history of any vascular disease or chronic illness. All subjects
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were above 18 years of age. Blood samples were drawn from all
subjects and vitamin B12, folic acid and homocysteine levels
were estimated by chemiluminescent immunoassay. Seventy three
of these hundred patients of vascular disease were followed up for
six months during which time they were administered various
homocysteine-lowering vitamin regimen. At the end of six months,
their blood samples were drawn and a repeat homocysteine
estimation done. Statistical analysis of the data was done by the
SPSS 17 statistical package (SPSS, Chicago, IL). Data was
expressed as mean ± SEM. Significance of association was deter-
mined by regression analysis, Student’s t test and correlation
studies.
Results
As shown in Table 1, vitamin B12 levels were found to be
similar in controls and patients, as a whole, and even when taken
as individual categories (CAD, CVD and PVD). Folate levels
were significantly reduced (though well within the Biological
Reference Interval-BRI) in the patients as compared to the
controls. Amongst the different categories of patients, it was
significantly reduced in patients of CAD and CVD, but not in
patients of PVD. Homocysteine levels were significantly higher
in all patient categories as compared to the controls. As seen in
Tables 2 and 3, homocysteine levels bore a negative correlation
with vitamin B12 levels as well as with folic acid levels. Table 2
depicts the correlation of homocysteine levels with those of
vitamin B12 in controls as well as patients of vascular disease.
In controls, homocysteine levels bore an insignificant negative
correlation with vitamin B12 levels. When patients of vascular
disease were taken as a whole, homocysteine levels bore a signifi-
cant negative correlation with B12 levels. This significance was
due to the significant negative correlation between homocysteine
levels and vitamin B12 levels in patients of CVD and PVD. In
CAD, too, homocysteine levels bore a negative correlation with
vitamin B12 levels, but this was not significant.
Table 3 depicts the correlation of homocysteine levels with
concentration of folic acid levels in controls as well as patients.
In controls, homocysteine levels bore a significant negative corre-
lation with folic acid levels. In patients, too, the negative
correlation between homocysteine levels and folic acid levels was
highly significant. In patients of CAD and CVD, this negative
correlation was significant, but in patients of PVD, it was in-
significant.
Fig. 1. Homocysteine metabolism and its relation with folate cycle.doi: 10.3164/jcbn.11-72
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Thus, it is observed that -folic acid levels were significantly
less in CAD and CVD patients as compared to controls, -vitamin
B12 levels were not significantly reduced in any patient category
as compared to controls, -in CAD, homocysteine levels bore a
significant negative correlation with folic acid levels, but not with
vitamin B12 levels, -in CVD, homocysteine levels bore a signifi-
cant negative correlation with vitamin B12 levels as well as folic
acid levels, -in PVD, homocysteine levels bore a significant corre-
lation only with vitamin B12 levels but not with folic acid levels.
This indicates that the vascular morbidity due to hyperhomo-
cysteinemia could be due, at least partly, to relative deficiencies
of folate and vitamin B12. Estimation of homocysteine levels was
repeated in the plasma of seventy three patients on different
regimen of vitamin therapy to ascertain their response. Forty one
patients received a single daily dose of 5 mg of folic acid, and 33
received a combination of 500 mg of cobalamine (vitamin B12)
and 1.5 mg of folate (folic acid). Repeat estimation of homo-
cysteine was done at the end of 6 months and the average decrease
in plasma homocysteine levels calculated. The response to therapy
(in terms of percentage reduction of homocysteine over a period
of six months) was similar in the patients receiving a single daily
dose of only 5 mg folate (39.17%) and those receiving a combina-
tion of 1.5 mg of folate and 500 mg cobalamine (37.02%).
The patients receiving a single daily dose of 5 mg folate were
further categorized into those with folate deficiency (i.e. folate
<3.0 ng/mL), those with normal folate levels but below the mean
of the BRI (folate 3.0 to 10.0 ng/mL), and those with normal
folate with values above the BRI mean (folate >10.0 ng/mL). The
reduction in plasma homocysteine concentrations achieved in 6
months was similar in all three categories (p value ranging from
0.9987 to 0.3266). Similarly these patients were again segregated
into three categories on basis of their vitamin B12 levels (B12
<220 pg/mL; B12 220 to 590 pg/mL and B12 >590 pg/mL. Again
the reduction in plasma homocysteine concentrations achieved
was not significantly different in the three categories (Tables 4
and 5). A similar exercise of segregation of patients receiving a
combination of 500 mg of B12 and 1.5 mg of folate, on basis of
their folate levels or their B12 levels revealed that the reduction in
plasma homocysteine concentrations achieved in all the categories
was similar.
Discussion
In the developing countries, India being one of them, the
increased incidence of vascular disease adds to the continuing
burden of infectious, nutritional and perinatal diseases, which
has been termed the double burden. (1997–1999 World Health
Statistics). Also, Yusuf et al.(1) reported that the predominant
Table 1. Serum levels of vitamin B12, folic acid and homocysteine in controls and patients
p values here are comparison of each group with controls. *p<0.05 significant. **p<0.005 highly significant. Homocys-
teine concentrations were significantly lower in all patient categories as compared to controls. However, only folic
acid levels were significantly lower in patients of CAD and CVD than in controls. The levels of both vitamin B12 and
folic acid were within the BRI in controls as well as patients.
Category Vitamin B12 in pg/mL 
Mean ± SEM
Folic Acid in ng/mL 
Mean ± SEM
Homocysteine in μmol/L 
Mean ± SEM
Controls 
[n =1 0 0 ] 505.69 ± 29.98 13.04 ± 0.71 12.42 ± 0.85
All Patients 
[n =1 0 0 ]
506.18 ± 30.47 9.51 ± 0.61 22.33 ± 2.06
p =0 . 9 9 1 p = 0.000** p = 0.000**
CAD 
[n =3 5 ]
516.74 ± 50.89 8.40 ± 0.71 27.17 ± 4.16
p =0 . 8 7 4 p = 0.001** p = 0.000**
CVD 
[n =3 5 ]
588.86 ± 58.27 9.49 ± 1.28 19.30 ± 2.41
p =0 . 2 2 3 p = 0.004** p = 0.000**
PVD 
[n =3 0 ]
397.40 ± 41.06 10.84 ± 1.11 20.21 ± 3.71
p =0 . 1 1 6 p =0 . 0 7 8 p = 0.000**
Table 2. Correlation between plasma homocysteine and serum vitamin
B12 levels
*p<0.05 significant. **p<0.005 highly significant. Despite vitamin B12
levels being within the BRI in all patients of disease, plasma homo-
cysteine bore a significant negative correlation with vitamin B12 in
patients of CVD and PVD.
Category Correlation p value
Controls 
[n = 100] −0.165 0.102
All Patients 
[n = 100] −0.263 0.008*
CAD 
[n =3 5 ] −0.111 0.526
CVD 
[n =3 5 ] −0.426 0.011*
PVD 
[n =3 0 ] −0.46 0.010*
Table 3. Correlation between plasma homocysteine and serum folic
acid levels
*p<0.05 significant. **p<0.005 highly significant. Plasma homocysteine
levels bore a significant negative correlation with folate levels in
controls as well as patients of CAD and CVD.
Category Correlation p value
Controls 
[n = 100] −0.241 0.016*
All Patients 
[n = 100] −0.294 0.003**
CAD 
[n =3 5 ] −0.349 0.040*
CVD 
[n =3 5 ] −0.377 0.025**
PVD 
[n =3 0 ] −0.208 0.271 J. Clin. Biochem. Nutr. | May 2012 | vol. 50 | no. 3 | 225
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diseases are now atherosclerotic vascular disease, 80% of such
cases being found in the developing countries. Thus, we are faced
with a double burden as well as 80% of the global burden of
vascular disease. Hence, it is imperative that our efforts should be
continuous and unslackened towards identifying all risk factors,
for vasculardisease especially, and taking appropriate action to
minimize their pathogenecity and, thereby, reduce the morbidity
and mortality due to vascular disease the world over.
Many cross-sectional and case-control studies have demon-
strated the association of homocysteine with occlusive vascular
disease.(3–6) Most of these studies have been conducted in a variety
of populations, but did not include subjects from the Indian
subcontinent. Since 80% of the global burden of vascular disease
is in the developing countries (India being one of them), it follows
that there is a need to gather data from the Indian subcontinent
and subsequently institute appropriate preventive measures. The
role of vitamin B12 and folate in the metabolism of homocysteine
is shown in Fig. 1. When either folate or B12 are deficient, the
remethylation of homocysteine slows down, homocysteine
accumulates and its level in the circulation rises, predisposing to
atherothrombotic plaque formation.
As revealed in Table 1, the mean levels of the vitamins B12 and
folate in controls as well as patients were well within the BRI, but
the mean folate level in vascular disease patients was significantly
less (p = 0.000) than that in the controls (even though it was within
the BRI). This significance was due to the significantly lower
levels of folate in the patients of CAD and CVD as compared to
those in controls (Table 3). This would confer an association of
folate with CAD and CVD categories of vascular disease, even
within its BRI.
In many Western and European populations, it has been
reported by at least 10 scientists that homocysteine decreases as
folate levels increase.(8,11–20) The results of our study corroborate
these observations. We found that serum folate levels correlated
negatively with the plasma homocysteine concentrations in patients
of vascular disease and healthy controls. Also, Sauberlich et al.(21)
demonstrated that dietary intake of folate reflects biochemically
measured folate status. Hence, it would follow that increasing
dietary folate would increase serum folate and, thereby, reduce
plasma homocysteine concentrations. The end result would be
reduction of risk of vascular disease. This has also been demon-
strated by several scientists in Western and European populations
even in subjects with normal levels of folate.(9,13,22–27)
On the other hand, vitamin B12 supplements have been found
to be effective in lowering homocysteine only in those with overt
cobalamin deficiency.(9,23,28,29) Since most of our subjects (controls
as well as patients) had normal B12 levels, there should have been
a lack of correlation between homocysteine levels and vitamin B12
levels; but this was not observed to be so in our vascular disease
patients group in whom there was a significant negative correla-
tion between plasma homocysteine concentrations and serum
vitamin B12 levels (Table 2). This may indicate the need to revise
the BRI of vitamin B12 in the developing countries.
It has been demonstrated that the risk of vascular disease is
40% higher in Indians as compared to Europeans,(30) and that
Indians are prone to vascular disease 5–10 years earlier than
other ethnicities, and the disease progression is more severe.(31) In
addition, the Western and European countries are amongst the
more developed countries as compared to India (which is a
developing country), and nutritional deficiencies are part of our
double burden of disease. This would indicate that dietary supple-
ments would be even more effective in our population. As
evidenced by our current data, dietary supplements with folate
as well as vitamin B12 should benefit us. In keeping with this line
of thought, we followed up 73 patients for 6 months and did a
repeat estimation of homocysteine thereafter. These patients were
on different regimen of homocysteine-lowering vitamin therapy:
forty-one patients received a single daily dose of 5 mg of folic
acid, thirty-three patients received a combination of 500 mg of
B12 and 1.5 mg of folic acid everyday.
The administration of a single daily dose of 5 mg of folic acid
achieved as much reduction in homocysteine levels as the
combination of folate (1.5 mg) and vitamin B12 (500 mg). These
are higher doses of folate than suggested by previous reports.(32)
The reduction in homocysteine levels achieved (37.02%) by the
daily administration of a combination of 500 μg of B12 and 1.5 mg
of folic acid was similar to that achieved by the administration of
a single daily dose of 5 mg of folate (39.17%). This was irrespec-
tive of the presence or absence of individual deficiencies of folate
or vitamin B12, or even the concurrent presence of deficiencies of
both these vitamins.
Thus, we see that in Indians, vascular disease due to hyper-
homocysteinemia is correlated to the serum folate and vitamin B12
concentrations. Also, a single daily dose of 5 mg of folic acid is as
effective in reducing homocysteine, as a combination of 500 μg of
B12 and 1.5 mg of folic acid, even when the serum vitamin levels
are within the BRI.
The Food and Drug Administration (FDA), USA, has discussed
food fortification of flours and cereal products at 350 mg of folate
per 100 gram of flour/cereal as the best means of population folate
supplementation for the prevention of neural tube defects in the
American population. Boushey et al.(32) projected that such a
fortification would annually prevent 50,000 deaths due to CAD,
alone, in the Western population. There is, therefore, a need to
extrapolate these data to North Indian urban population, keeping
in mind that as per epidemiological transition, India is weighed
down by a double burden of disease nutritional deficiencies as
well as degenerative diseases (e.g. vascular disease). It would
follow that not only is there a greater need for folate supple-
mentation, but also that probably a higher dose (equivalent of
Table 4. Response to single daily dose of 5 mg folic acid in terms of
reduction of homocysteine levels over a period of 6 months
Patients of vascular disease who had received a single daily dose of
5 mg folate for 6 months were segregated first on basis of their folate
levels and then on the basis of their B12.
Patient group No. of 
patients
Average % reduction in plasma 
homocysteine levels
Folate <3 ng/mL 6 51.3
Folate 3–10 ng/mL 28 42.59 [p =0 . 8 6 5 ]
Folate >10 ng/mL 7 24.31 [p =0 . 9 9 9 ]
B12 <220 pg/mL 16 42.18 [p =0 . 9 6 4 ]
B12 = 220–590 pg/mL 17 37.84 [p =0 . 8 8 6 ]
B12 >590 pg/mL 8 34.78 [p =0 . 9 9 6 ]
Table 5. Response to combined daily dose of 1.5 mg folate and 500 μg
cobalamine in terms of reduction of homocysteine levels over a period
of 6 months
Patients of vascular disease who had received combination of 1.5 mg
folic acid and 500 μg cobalamine were segregated first on basis of their
folate levels and then on basis of their vitamin B12 levels. The average
percentage reduction in homocysteine levels was not significantly
different in any group.
Patient group No. of 
patients
Average % reduction in plasma 
homocysteine levels
Folate <3 ng/mL 4 37.76
Folate 3–10 ng/mL 19 32.89 [p =0 . 3 2 9 ]
Folate >10 ng/mL 8 41.27 [p =0 . 4 0 8 ]
B12 <220 pg/mL 9 46.00 [p =0 . 5 1 5 ]
B12 = 220–590 pg/mL 16 36.22 [p =0 . 3 5 6 ]
B12 >590 pg/mL 7 33.12 [p =0 . 3 7 4 ]doi: 10.3164/jcbn.11-72
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daily dietary intake of 1.5 mg of folate) would be required to be
equally effective.
Hankey and Eikelboom(32) described a potential hazard of therapy
with folate alone. Progressive neurological damage (subacute
combined degeneration of the spinal cord) has been seen in
subjects with subclinical vitamin B12 deficiency in whom folic
acid therapy may mask the development of the haematological
manifestations of the B12 deficiency.
In view of the above-mentioned hazard of folate therapy, and
the fact that the homocysteine lowering effect of 5 mg of folate
alone as well as a combination of folate (1.5 mg) and cobalamin
(500 mg) are similar, food fortification with both these cheap,
easily available, water-soluble vitamins would best benefit the
North Indian population. It would, hence, be pertinent to suggest
that scientists, clinicians and policy-makers in our country should
further evaluate the relevance of food fortification with folate
and vitamin B12 so as to correct nutritional deficiencies as well as
reduce risk for vascular disease—the double benefit for the double
burden of disease in the developing countries.
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